Mazdutide approved in US in 2025
3
Ṁ100Ṁ295resolved Jan 4
Resolved
NO1H
6H
1D
1W
1M
ALL
Mazdutide, a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics and Eli Lilly, has shown promising results in weight management. It received approval from China's NMPA in June 2025. This market predicts whether the FDA will approve mazdutide for weight management in the U.S. before December 22, 2025. Resolution will be based on official FDA announcements.
This question is managed and resolved by Manifold.
Market context
Get 
1,000 to start trading!
1,000🏅 Top traders
| # | Trader | Total profit |
|---|---|---|
| 1 | Ṁ51 | |
| 2 | Ṁ20 | |
| 3 | Ṁ1 |
People are also trading
Related questions
Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?
41% chance
When will retatrutide receive full FDA approval, making it legal to prescribe in the United States?
Any myostatin inhibitor FDA approved by 2027
63% chance
Will a drug to be used by most healthy adults be approved by 2043 year end?
72% chance
FDA approves YCT-529 male birth control pill before 2035?
36% chance
Will a drug that didn't go through human clinical trials be approved by 2034?
27% chance
💊Will INS018_055 be FDA-approved by 2030?
48% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
28% chance
Will 10 million Americans be on semaglutide (or yet-to-be-approved equally good or superior alternatives) by the end of 2030?
78% chance
Will AOH1996 be FDA approved before 2040?
40% chance